ArticleThe EPMA journal2021
Association of systemic inflammation indices with visual field loss progression in patients with primary angle-closure glaucoma: potential biomarkers for 3P medical approaches.
Article in The EPMA journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Prediction of primary glaucoma: development and validation of multiple machine learning models.Scientific reports · 2026Article
- Routine blood tests and machine learning identify complications in high myopia.Nature communications · 2026Article
- Association of serum TIM-3 and Galectin-9 levels with glaucoma progression: implications for clinical monitoring.American journal of translational research · 2026Article
- Developing and validating an explainable clinlabomics-based machine-learning model for screening primary angle-closure glaucoma in the context of PPPM.The EPMA journal · 2025Article
- Association of systemic inflammatory biomarkers with ocular disease: a large population-based cross-sectional study.European journal of medical research · 2025Article
- Association between 91 circulating inflammatory proteins and the risk of glaucoma: A Mendelian randomization study.Scientific reports · 2025Article
- Gut-tropic α4β7Frontiers in immunology · 2025Article
- Evaluation of hematological markers as prognostic tools in rheumatoid arthritis.BMC rheumatology · 2024Article
- Genetic association of lipid traits and lipid-related drug targets with normal tension glaucoma: a Mendelian randomization study for predictive preventive and personalized medicine.The EPMA journal · 2024Article
- Article
- Th1 cells contribute to retinal ganglion cell loss in glaucoma in a VCAM-1-dependent manner.Journal of neuroinflammation · 2024Article
- α-1 antitrypsin is promising for the identification of glaucoma severity and is associated with glaucomatous neural damage.Biomarkers in medicine · 2024Article
- Association of plasma lactoferrin levels with disease severity in glaucoma patients.Frontiers in medicine · 2024Article
- Role of Inflammation in Canine Primary Glaucoma.Animals : an open access journal from MDPI · 2023Review
- The correlation between primary open-angle glaucoma (POAG) and gut microbiota: a pilot study towards predictive, preventive, and personalized medicine.The EPMA journal · 2023Article
- Development and validation of a routine blood parameters-based model for screening the occurrence of retinal detachment in high myopia in the context of PPPM.The EPMA journal · 2023Article
- New insight of metabolomics in ocular diseases in the context of 3P medicine.The EPMA journal · 2023Review
- Blood cell traits and risk of glaucoma: A two-sample mendelian randomization study.Frontiers in genetics · 2023Article
- Association of Serum Complement C1q and C3 Level with Age-Related Macular Degeneration in Women.Journal of inflammation research · 2022Article
- Clinical Significance of Albumin- and Bilirubin-Based Biomarkers in Glaucoma: A Retrospective Case-Control Study.Oxidative medicine and cellular longevity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
relevanceAccumulating evidence suggests a dysfunction of the para-inflammation in the retinal ganglion cell layer and the optic nerve head in patients with glaucoma. Currently, circulating blood platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR) are regarded as novel indicators of systemic inflammation. Biomarkers allow early identification of patients with visual field (VF) loss progression and timely implementation of replacement therapies.
objectiveThis study aimed to investigate whether higher inflammatory indices (PLR, NLR, and LMR) were associated with VF loss progression in patients with primary angle-closure glaucoma (PACG) for the predictive diagnostics, targeted prevention, and personalization of medical services.
methodsThis prospective cohort study followed up 277 patients with PACG for at least 24 months, with clinical examination and VF testing every 6 months. Inflammatory cell quantification, including platelets, neutrophils, lymphocytes, and monocytes, was measured using the Sysmex XN-A1 automated inflammatory cells quantification system. Three systemic inflammatory indices, PLR, NLR, and LMR, were determined on the basis of baseline neutrophil, lymphocyte, monocyte, and platelet counts in patients with PACG. The risk factors for PACG were analyzed using logistic regression, Cox proportional hazards regression, and the Kaplan-Meier curve.
resultsOur results revealed that 111 (40.07%) patients showed VF loss progression. The PLR was significantly higher (
conclusionOur findings revealed the significant association between a high PLR and a greater risk of VF loss progression in patients with PACG. PLR may be highly recommended as a novel predictive/diagnostic tool for the assessment of VF loss progression from the perspectives of predictive, preventive, and personalized medicine in vulnerable populations and for individual screening. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13167-021-00260-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.